Targeting HIV-1 envelope glycoprotein trimers to B cells by using APRIL improves antibody responses

Journal of Virology

Volumn 86, Issue 5, 2012, Pages 2488-2500

  Melchers, Mark ^a   Bontjer, Ilja ^a   Tong, Tommy ^b   Chung, Nancy P Y ^c   Klasse, Per Johan ^c   Eggink, Dirk ^a,f   Montefiori, David C ^d   Gentile, Maurizio ^e   Cerutti, Andrea ^e,f   Olson, William C ^g   Berkhout, Ben ^a   Binley, James M ^b   Moore, John P ^c   Sanders, Rogier W ^a,c  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b TORREY PINES INSTITUTE FOR MOLECULAR STUDIES   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e HOSPITAL DEL MAR   (Spain)

^f MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^g A Subsidiary of Lantheus Holdings   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATION INDUCED CYTIDINE DEAMINASE; APRIL PROTEIN; B CELL ACTIVATING FACTOR; CD40 LIGAND; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 140; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; NEUTRALIZING ANTIBODY;

ANIMAL EXPERIMENT; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; B LYMPHOCYTE; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOGLOBULIN PRODUCTION; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING;

ANIMALS; ANTIBODY FORMATION; B-LYMPHOCYTES; CELL LINE; CELLS, CULTURED; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; NEUTRALIZATION TESTS; PROTEIN MULTIMERIZATION; RABBITS; RECOMBINANT FUSION PROTEINS; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 13;

HUMAN IMMUNODEFICIENCY VIRUS 1; ORYCTOLAGUS CUNICULUS;

EID: 84863393454     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.06259-11     Document Type: Article

References (109)

1. Banerjee K, et al. 2009. Enzymatic removal of mannose moieties can increase the immune response to HIV-1 gp120 in vivo. Virology 389:108-121.
2. Barouch, D. H., and B. Korber. 2010. HIV-1 vaccine development after STEP. Annu. Rev. Med. 61:153-167.
3. Beddows S, et al. 2007. A comparative immunogenicity study in rabbits of disulfide-stabilized, proteolytically cleaved, soluble trimeric human immunodeficiency virus type 1 gp140, trimeric cleavage-defective gp140 and monomeric gp120. Virology 360:329-340.
4. Beddows S, et al. 2005. Evaluating the immunogenicity of a disulfidestabilized, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. J. Virol. 79:8812-8827.
5. Binley JM, et al. 2008. Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. J. Virol. 82:11651-11668.
6. Binley JM, et al. 2000. A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure. J. Virol. 74:627-643.
7. Binley JM, et al. 2002. Enhancing the proteolytic maturation of human immunodeficiency virus type 1 envelope glycoproteins. J. Virol. 76:2606-2616.
8. Bontjer I, et al. 2009. Optimization of human immunodeficiency virus type 1 envelope glycoproteins with V1/V2 deleted, using virus evolution. J. Virol. 83:368-383.
9. Bontjer I, et al. 2010. Stabilized HIV-1 envelope glycoprotein trimers lacking the V1V2 domain, obtained by virus evolution. J. Biol. Chem. 285:36456-36470.
10. Boscardin SB, et al. 2006. Antigen targeting to dendritic cells elicits long-lived T cell help for antibody responses. J. Exp. Med. 203:599-606.
11. Bossen C, et al. 2008. TACI, unlike BAFF-R, is solely activated by oligomeric BAFF and APRIL to support survival of activated B cells and plasmablasts. Blood 111:1004-1012.
12. Bower JF, Yang X, Sodroski J, Ross TM. 2004. Elicitation of neutralizing antibodies with DNA vaccines expressing soluble stabilized human immunodeficiency virus type 1 envelope glycoprotein trimers conjugated to C3d. J. Virol. 78:4710-4719.
13. Buchbinder SP, et al. 2008. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372:1881-1893.
14. Burton DR, et al. 2004. HIV vaccine design and the neutralizing antibody problem. Nat. Immunol. 5:233-236.
15. Burton DR, et al. 1994. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 266:1024-1027.
16. Caminschi I, et al. 2008. The dendritic cell subtype-restricted C-type lectin Clec9A is a target for vaccine enhancement. Blood 112:3264-3273.
17. Caux C, et al. 1994. Activation of human dendritic cells through CD40 cross-linking. J. Exp. Med. 180:1263-1272.
18. Chang SK, Mihalcik SA, Jelinek DF. 2008. B lymphocyte stimulator regulates adaptive immune responses by directly promoting dendritic cell maturation. J. Immunol. 180:7394-7403.
19. Chen TT, Tao MH, Levy R. 1994. Idiotype-cytokine fusion proteins as cancer vaccines. Relative efficacy of IL-2, IL-4, and granulocytemacrophage colony-stimulating factor. J. Immunol. 153:4775-4787.
20. Chu VT, Enghard P, Riemekasten G, Berek C. 2007. In vitro and in vivo activation induces BAFF and APRIL expression in B cells. J. Immunol. 179:5947-5957.
21. Corti D, et al. Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. PLoS One 5:e8805.
22. Crooks ET, et al. 2008. Relationship of HIV-1 and SIV envelope glycoprotein trimer occupation and neutralization. Virology 377:364-378.
23. Crooks ET, Tong T, Osawa K, Binley JM. 2011. Enzyme digests eliminate nonfunctional Env from HIV-1 particle surfaces, leaving native Env trimers intact and viral infectivity unaffected. J. Virol. 85:5825-5839.
24. Daly LM, et al. 2005. Innate IL-10 promotes the induction of Th2 responses with plasmid DNA expressing HIV gp120. Vaccine 23:963-974.
25. De Milito A, et al. 2004. Mechanisms of hypergammaglobulinemia and impaired antigen-specific humoral immunity in HIV-1 infection. Blood 103:2180-2186.
26. Dillon SR, Gross JA, Ansell SM, Novak AJ. 2006. An APRIL to remember: novel TNF ligands as therapeutic targets. Nat. Rev. Drug Discov. 5:235-246.
27. Eckl-Dorna J, Batista FD. 2009. BCR-mediated uptake of antigen linked to TLR9 ligand stimulates B-cell proliferation and antigen-specific plasma cell formation. Blood 113:3969-3977.
28. Eggink D, et al. 2009. Detailed mechanistic insights into HIV-1 sensitivity to three generations of fusion inhibitors. J. Biol. Chem. 284:26941-26950.
29. Eggink D, Melchers M, Sanders RW. 2007. Antibodies to HIV-1: aiming at the right target. Trends Microbiol. 15:291-294.
30. Eggink D, et al. 2010. Lack of complex N-glycans on HIV-1 envelope glycoproteins preserves protein conformation and entry function. Virology 401:236-247.
31. Faulkner L, et al. 2001. IL-2 linked to a peptide from influenza hemagglutinin enhances T cell activation by affecting the antigen-presentation function of bone marrow-derived dendritic cells. Int. Immunol. 13:713-721.
32. Flynn NM, et al. 2005. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J. Infect. Dis. 191:654-665.
33. Forsell MN, Schief WR, Wyatt RT. 2009. Immunogenicity of HIV-1 envelope glycoprotein oligomers. Curr. Opin. HIV AIDS 4:380-387.
34. Gilbert PB, et al. 2005. Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial. J. Infect. Dis. 191:666-677.
35. Goodnow CC, Sprent J, Fazekas de St Groth B, Vinuesa CG. 2005. Cellular and genetic mechanisms of self tolerance and autoimmunity. Nature 435:590-597.
36. +T cell decline and high viral load during acute infection. J. Virol. 85:4828-4840.
37. Green TD, Montefiori DC, Ross TM. 2003. Enhancement of antibodies to the human immunodeficiency virus type 1 envelope by using the molecular adjuvant C3d. J. Virol. 77:2046-2055.
38. Groom JR, et al. 2007. BAFF and MyD88 signals promote a lupuslike disease independent of T cells. J. Exp. Med. 204:1959-1971.
39. Harris, A, et al. 2011. Trimeric HIV-1 glycoprotein gp140 immunogens and native HIV-1 envelope glycoproteins display the same closed and open quaternary molecular architectures. Proc. Natl. Acad. Sci. U. S. A. 108:11440-11445.
40. He B, et al. 2006. HIV-1 envelope triggers polyclonal Ig class switch recombination through a CD40-independent mechanism involving BAFF and C-type lectin receptors. J. Immunol. 176:3931-3941.
41. Heath AW, Devey ME, Brown IN, Richards CE, Playfair JH. 1989. Interferon-gamma as an adjuvant in immunocompromised mice. Immunology 67:520-524.
42. Heath AW, Playfair JH. 1990. Conjugation of interferon-gamma to antigen enhances its adjuvanticity. Immunology 71:454-456.
43. Herrera C, et al. 2003. Nonneutralizing antibodies to the CD4-binding site on the gp120 subunit of human immunodeficiency virus type 1 do not interfere with the activity of a neutralizing antibody against the same site. J. Virol. 77:1084-1091.
44. Ingold K, et al. 2005. Identification of proteoglycans as the APRILspecific binding partners. J. Exp. Med. 201:1375-1383.
45. Kang YK, et al. 2009. Structural and immunogenicity studies of a cleaved, stabilized envelope trimer derived from subtype A HIV-1. Vaccine 27:5120-5132.
46. Kern C, et al. 2004. Involvement of BAFF and APRIL in the resistance to apoptosis of B-CLL through an autocrine pathway. Blood 103:679-688.
47. Kimberley FC, et al. 2009. The proteoglycan (heparan sulfate proteoglycan) binding domain of APRIL serves as a platform for ligand multimerization and cross-linking. FASEB J. 23:1584-1595.
48. Kirschner M, et al. 2006. The production of cleaved, trimeric human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein vaccine antigens and infectious pseudoviruses using linear polyethylenimine as a transfection reagent. Protein Expr. Purif. 48:61-68.
49. Klasse PJ, Sanders RW, Cerutti A, Moore JP. 17 April 2011, posting date. How can HIV-type-1-Env immunogenicity be improved to facilitate antibody-based vaccine development? AIDS Res. Hum. Retroviruses doi:10.1089/aid.2011.0053.
50. Koch M, Frazier J, Sodroski J, Wyatt R. 2005. Characterization of antibody responses to purified HIV-1 gp120 glycoproteins fused with the molecular adjuvant C3d. Virology 340:277-284.
51. Kwong PD, Wilson IA. 2009. HIV-1 and influenza antibodies: seeing antigens in new ways. Nat. Immunol. 10:573-578.
52. Li M, et al. 2005. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J. Virol. 79:10108-10125.
53. Lim YS, et al. 1998. Vaccination with an ovalbumin/interleukin-4 fusion DNA efficiently induces Th2 cell-mediated immune responses in an ovalbumin-specific manner. Arch. Pharm. Res. 21:537-542.
54. Litinskiy MB, et al. 2002. DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL. Nat. Immunol. 3:822-829.
55. Ma DY, Clark EA. 2009. The role of CD40 and CD154/CD40L in dendritic cells. Semin. Immunol. 21:265-272.
56. Mackay F, Schneider P. 2009. Cracking the BAFF code. Nat. Rev. Immunol. 9:491-502.
57. Mackay F, Schneider P. 2008. TACI, an enigmatic BAFF/APRIL receptor, with new unappreciated biochemical and biological properties. Cytokine Growth Factor Rev. 19:263-276.
58. Mackay F, Schneider P, Rennert P, Browning J. 2003. BAFF AND APRIL: a tutorial on B cell survival. Annu. Rev. Immunol. 21:231-264.
59. Martinelli E, et al. 2007. HIV-1 gp120 inhibits TLR9-mediated activation and IFN-{alpha} secretion in plasmacytoid dendritic cells. Proc. Natl. Acad. Sci. U. S. A. 104:3396-3401.
60. Mascola JR, Montefiori DC. 2010. The role of antibodies in HIV vaccines. Annu. Rev. Immunol. 28:413-444.
61. McCormick AL, Thomas MS, Heath AW. 2001. Immunization with an interferon-gamma-gp120 fusion protein induces enhanced immune responses to human immunodeficiency virus gp120. J. Infect. Dis. 184:1423-1430.
62. McElrath MJ, et al. 2008. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet 372:1894-1905.
63. Melchers M, et al. 2011. A stabilized HIV-1 envelope glycoprotein trimer fused to CD40 ligand targets and activates dendritic cells. Retrovirology 8:48.
64. Mestecky J, et al. 2004. Paucity of antigen-specific IgA responses in sera and external secretions of HIV-type 1-infected individuals. AIDS Res. Hum. Retroviruses 20:972-988.
65. Mestecky J, Moldoveanu Z, Smith PD, Hel Z, Alexander RC. 2009. Mucosal immunology of the genital and gastrointestinal tracts and HIV-1 infection. J. Reprod. Immunol. 83:196-200.
66. Mikell I, et al. Characteristics of the earliest cross-neutralizing antibody response to HIV-1. PLoS Pathog. 7:e1001251.
67. Moore PL, et al. 2006. Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1. J. Virol. 80:2515-2528.
68. Muster T, et al. 1993. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J. Virol. 67:6642-6647.
69. Nakaya HI, et al. 2011. Systems biology of vaccination for seasonal influenza in humans. Nat. Immunol. 12:786-795.
70. Nayak BP, Sailaja G, Jabbar AM. 2003. Enhancement of gp120-specific immune responses by genetic vaccination with the human immunodeficiency virus type 1 envelope gene fused to the gene coding for soluble CTLA4. J. Virol. 77:10850-10861.
71. Nchinda G, et al. 2008. The efficacy of DNA vaccination is enhanced in mice by targeting the encoded protein to dendritic cells. J. Clin. Invest. 118:1427-1436.
72. Nimal S, Heath AW, Thomas MS. 2006. Enhancement of immune responses to an HIV gp120 DNA vaccine by fusion to TNF alpha cDNA. Vaccine 24:3298-3308.
73. Nimal S, McCormick AL, Thomas MS, Heath AW. 2005. An interferon gamma-gp120 fusion delivered as a DNA vaccine induces enhanced priming. Vaccine 23:3984-3990.
74. Pantophlet R, Burton DR. 2006. GP120: target for neutralizing HIV-1 antibodies. Annu. Rev. Immunol. 24:739-769.
75. Parren PW, Sattentau QJ, Burton DR. 1997. HIV-1 antibody-debris or virion? Nat. Med. 3:366-367.
76. Pitisuttithum P, et al. 2006. Randomized, double-blind, placebocontrolled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J. Infect. Dis. 194:1661-1671.
77. Poignard P, et al. 2003. Heterogeneity of envelope molecules expressed on primary human immunodeficiency virus type 1 particles as probed by the binding of neutralizing and nonneutralizing antibodies. J. Virol. 77:353-365.
78. Querec TD, et al. 2009. Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat. Immunol. 10:116-125.
79. Reitter JN, Means RE, Desrosiers RC. 1998. A role for carbohydrates in immune evasion in AIDS. Nat. Med. 4:679-684.
80. Rerks-Ngarm S, et al. 2009. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 361:2209-2220.
81. Robb ML. 2008. Failure of the Merck HIV vaccine: an uncertain step forward. Lancet 372:1857-1858.
82. Sailaja G, Husain S, Nayak BP, Jabbar AM. 2003. Long-term maintenance of gp120-specific immune responses by genetic vaccination with the HIV-1 envelope genes linked to the gene encoding Flt-3 ligand. J. Immunol. 170:2496-2507.
83. Sanders RW, et al. 2002. Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. J. Virol. 76:8875-8889.
84. Sather DN, et al. 2009. Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J. Virol. 83:757-769.
85. Scapini P, Bazzoni F, Cassatella MA. 2008. Regulation of B-cellactivating factor (BAFF)/B lymphocyte stimulator (BLyS) expression in human neutrophils. Immunol. Lett. 116:1-6.
86. Schäfer F, et al. 2002. Lack of simian immunodeficiency virus (SIV) specific IgA response in the intestine of SIV infected rhesus macaques. Gut 50:608-614.
87. Schägger H, Cramer WA, von Jagow G. 1994. Analysis of molecular masses and oligomeric states of protein complexes by blue native electrophoresis and isolation of membrane protein complexes by twodimensional native electrophoresis. Anal. Biochem. 217:220-230.
88. Schägger H, von Jagow G. 1991. Blue native electrophoresis for isolation of membrane protein complexes in enzymatically active form. Anal. Biochem. 199:223-231.
89. Scheid JF, et al. 2011. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 333:1633-1637.
90. Schneider JA, et al. 2007. Mucosal HIV-binding antibody and neutralizing activity in high-risk HIV-uninfected female participants in a trial of HIV-vaccine efficacy. J. Infect. Dis. 196:1637-1644.
91. Seaman MS, et al. 2010. Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. J. Virol. 84:1439-1452.
92. Shan M, et al. 2007. HIV-1 gp120 mannoses induce immunosuppressive responses from dendritic cells. PLoS Pathog. 3:e169.
93. Shreedhar V, et al. 1999. Dendritic cells require T cells for functional maturation in vivo. Immunity 11:625-636.
94. +T cells to produce IFN-gamma by an IL-12-independent but CD70-dependent mechanism in vivo. J. Exp. Med. 204:1095-1106.
95. Tighe H, et al. 2000. Conjugation of protein to immunostimulatory DNA results in a rapid, long-lasting and potent induction of cellmediated and humoral immunity. Eur. J. Immunol. 30:1939-1947.
96. Trkola A, et al. 1996. CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. Nature 384:184-187.
97. Trkola A, et al. 1995. Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG. J. Virol. 69:6609-6617.
98. van Gils MJ, Euler Z, Schweighardt B, Wrin T, Schuitemaker H. 2009. Prevalence of cross-reactive HIV-1-neutralizing activity in HIV-1- infected patients with rapid or slow disease progression. AIDS 23:2405-2414.
99. van Kooten C, Banchereau J. 2000. CD40-CD40 ligand. J. Leukoc. Biol. 67:2-17.
100. van Montfort T, et al. 2011. A chimeric HIV-1 envelope glycoprotein trimer with an embedded granulocyte-macrophage colony-stimulating factor (GM-CSF) domain induces enhanced antibody and T cell responses. J. Biol. Chem. 286:22250-22261.
101. Walker LM, et al. 2011. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 477:466-470.
102. Walker LM, et al. 2009. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326:285-289.
103. Wei X, et al. 2003. Antibody neutralization and escape by HIV-1. Nature 422:307-312.
104. + T cell responses in nonhuman primates. Proc. Natl. Acad. Sci. U. S. A. 102:15190-15194.
105. +T cell responses. J. Immunol. 174:7676-7683.
106. Wolf AI, et al. 2011. Protective antiviral antibody responses in a mouse model of influenza virus infection require TACI. J. Clin. Invest. 121:3954-3964.
107. Wu X, et al. 2010. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329:856-861.
108. Wu X, et al. 2011. Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science 333:1593-1602.
109. Xu W, et al. 2009. HIV-1 evades virus-specific IgG2 and IgA responses by targeting systemic and intestinal B cells via long-range intercellular conduits. Nat. Immunol. 10:1008-1017.